[1]秦艳,游志鹏,胡娇莉,等.糖尿病性黄斑水肿的药物治疗进展[J].眼科新进展,2018,38(3):281-284.[doi:10.13389/j.cnki.rao.2018.0066]
　QIN Yan,YOU Zhi-Peng,HU Jiao-Li,et al.Progresses in the agent treatment for diabetic macular edema[J].Recent Advances in Ophthalmology,2018,38(3):281-284.[doi:10.13389/j.cnki.rao.2018.0066]
点击复制

糖尿病性黄斑水肿的药物治疗进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年3期
页码:
281-284
栏目:
文献综述
出版日期:
2018-03-05

文章信息/Info

Title:
Progresses in the agent treatment for diabetic macular edema
作者:
秦艳; 游志鹏; 胡娇莉; 胡筱勤
330006　江西省南昌市，南昌大学第二附属医院眼科（秦艳，游志鹏，胡娇莉，胡筱勤）；330006　江西省南昌市，南昌大学研究生院医学部（秦艳）
Author(s):
QIN Yan; YOU Zhi-Peng; HU Jiao-Li; HU Xiao-Qin
Department of Ophthalmology，the Second Affiliated Hospital of Nanchang University（QIN Yan，YOU Zhi-Peng，HU Jiao-Li，HU Xiao-Qin），Nanchang 330006，Jiangxi Province，China；Nanchang University Graduate School of Medicine（QIN Yan），Nanchang 330006，Jiangxi Province，China
关键词:
糖尿病性黄斑水肿; 皮质类固醇缓释剂; 抗血管内皮生长因子药物; 治疗
Keywords:
diabetic macular edema; steroids drug delivery system; anti-vascular endothelial growth factor agent; therapy
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2018.0066
文献标志码:
A
摘要:
糖尿病性黄斑水肿是糖尿病患者眼部常见的并发症，也是导致糖尿病患者视力损伤的主要原因之一。糖尿病性黄斑水肿治疗方法较多，近年来药物治疗，特别是皮质类固醇药物缓释剂治疗发展迅速。本文就糖尿病性黄斑水肿的药物治疗进展作一综述。
Abstract:
Diabetic macular edema （DME），a common eye complication，is one of the main causes of visual impairment in diabetes patients.There are many treatments for DME.In recent years，drug therapy，especially the steroids drug delivery.This article will summarize the progress in drug treatment for DME.

参考文献/References:

［1］　GE J.Ophthalmology［M］.Beijing：People’s Medical Publishing House，2011：305.
葛坚.眼科学［M］.北京：人民卫生出版社，2011：305.
［2］　JING PY，PENG JJ，ZOU HD，WANG WW，FU J，BAI XL，et al.A 5-year prospective study of type 2 diabetes patients in Shanghai Xinjing Community 1.The incidence and risk factors of diabetic retinopathy and diabetic macular edema in Chinese type 2 diabetes residents［J］.Chin J Exp Ophthalmol，2016，34（4）：363-367.
金佩瑶，彭金娟，邹海东，王伟伟，傅炯，白雪林，等.上海市新泾社区2型糖尿病居民5年随访的前瞻性调查研究1.糖尿病视网膜病变和糖尿病黄斑水肿的发病率及危险因素［J］.中华实验眼科杂志，2016，34（4）：363-367.
［3］　NAUCK M，KARAKIULAKIS G，PERRUCHOUD AP，PAPAKONSTANTINOU E，ROTH M.Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells［J］.Eur J Pharmacol，1998，341（2-3）：309-315.
［4］　BECK RW.Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema［J］.Arch Ophthalmol，2009，127（3）：245-251.
［5］　NGUYEN QD.Retinal pharmacotherapy［M］.Beijing：People’s Military Medical Press，2013：63.
［6］　MALCLES A，DOT C，VOIRIN N，AGARD E，VIE AL，BELLOCQ D，et al.Real-life study in diabetic macular edema treated with dexamethasone implant：the reldex study［J］.Retina，2017，37（4）：753-760.
［7］　MATURI RK，POLLACK A，UY HS，VARANO M，GOMES AM，LI XY，et al.Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study［J］.Retina，2016，36（6）：1143-1152.
［8］　KHAN Z，KURIAKOSE RK，KHAN M，CHIN EK，ALMEIDA DR.Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy：meta-analysis and clinical implications［J］.Ophthalmic Surg Lasers Imaging Retina，2017，48（2）：160-166.
［9］　FRASER-BELL S，LIM LL，CAMPAIN A，MEHTA H，ARONEY C，BRYANT J，et al.Bevacizumab or dexamethasone implants for dme：2-year results（The BEVORDEX Study）［J］.Ophthalmology，2016，123（6）：1399-1401.
［10］　SHAH SU，HARLESS A，BLEAU L，MATURI RK.Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema［J］.Retina，2016，36（10）：1986-1996.
［11］　TOTAN Y，GULER E，GURAGAC FB.Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment［J］.Curr Eye Res，2016，41（1）：107-113.
［12］　HARITOGLOU C，MAYER W，WOLF A.Fluocinolone acetonide for the treatment of diabetic macular edema［J］.Exp Rev Clin Pharmacol，2016，9（3）：367-374.
［13］　EL-GHRABLY I，STEEL DH，HABIB M，VAIDEANU-COLLINS D，MANVIKAR S，HILLIER RJ.Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 microg/d intravitreal implant：real-world UK experience［J］.Eur J Ophthalmol，2017，27（3）：357-362.
［14］　FIGUEIRA J，HENRIQUES J，AMARO M，ROSAS V，ALVES D，CUNHA-VAZ J.A nonrandomized，open-label，multicenter，phase 4 pilot study on the effect and safety of iluvien（r） in chronic diabetic macular edema patients considered insufficiently responsive to available therapies（RESPOND）［J］.Ophthalmic Res，2017，57（3）：166-172.
［15］　PARRISH RN，TRAVERSO CE，GREEN K，DANIS RP.Quantitative assessment of optic nerve changes in patients with diabetic macular edema treated with fluocinolone acetonide vitreous implants［J］.Ophthalmic Surg Lasers Imaging Retina，2016，47（5）：418-425.
［16］　MEIRELES A，GOLDSMITH C，EL-GHRABLY I，ERGINAY A，HABIB M，PESSOA B，et al.Efficacy of 0.2 μg/day fluocinolone acetonide implant（ILUVIEN） in eyes with diabetic macular edema and prior vitrectomy［J］.Eye（Lond），2017，31（5）：684-690.
［17］　WYKOFF CC，CHAKRAVARTHY U，CAMPOCHIARO PA，BAILEY C，GREEN K，CUNHA-VAZ J.Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy［J］.Ophthalmology，2017，124（4）：440-449.
［18］　LANG GE.Diabetic macular edema［J］.Ophthalmologica，2012，227（Suppl 1）：21-29.
［19］　FERRARA N，GERBER HP，LECOUTER J.The biology of VEGF and its receptors［J］.Nat Med，2003，9（6）：669-676.
［20］　VAN BRONSWIJK H，DUBOIS EA，VAN GERVEN JM，COHEN AF.New drugs；natalizumab［J］.Ned Tijdschr Geneeskd，2008，152（9）：499-500.
［21］　VYAS S，THAPA R，BAJIMAYA S，PRADHAN E，PAUDYAL G.Anatomical and visual outcome of intravitreal bevacizumab（Avastin） in patients with diabetic macular edema［J］.Nepal J Ophthalmol，2016，8（15）：54-61.
［22］　SHIMURA M，YASUDA K，MINEZAKI T，NOMA H.Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema［J］.Jpn J Ophthalmol，2016，60（5）：401-407.
［23］　AREVALO JF，LASAVE AF，WU L，DIAZ-LLOPIS M，GALLEGO-PINAZO R，ALEZZANDRINI AA，et al.Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema：results of the Pan-american Collaborative Retina Study Group at 24 months［J］.Retina，2013，33（2）：403-413.
［24］　YU L，LIANG XH，FERRARA N.Comparing protein VEGF inhibitors：In vitro biological studies［J］.Biochem Biophys Res Commun，2011，408（2）：276-281.
［25］　DAI H，LU YY.Choice of current approaches to the management of diabetic macular edema［J］.Chin J Exp Ophthalmol，2016，34（12）：1061-1064.
戴虹，卢颖毅.糖尿病黄斑水肿治疗方案的选择及需要关注的几个问题［J］.中华实验眼科杂志，2016，34（12）：1061-1064.
［26］　BOYER DS，NGUYEN QD，BROWN DM，BASU K，EHRLICH JS.Outcomes with as-needed ranibizumab after initial monthly therapy：long-term outcomes of the phase Ⅲ RIDE and RISE trials［J］.Ophthalmology，2015，122（12）：2504-2513.
［27］　CHEN G，LI W，TZEKOV R，JIANG F，MAO S，TONG Y.Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema：a meta-analysis of randomized controlled trials［J］.PLoS One，2014，9（12）：e115797.
［28］　HIRANO T，TORIYAMA Y，IESATO Y，IMAI A，HIRABAYASHI K，NAGAOKA T，et al.Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation［J］.Jpn J Ophthalmol，2017，61（1）：51-60.
［29］　EHRLICH R，DAN I，DEITCH I，AXER-SIEGEL R，MIMOUNI K.The effectiveness of intravitreal ranibizumab in patients with diabetic macular edema who have failed to respond to intravitreal bevacizumab［J］.Ophthalmologica，2016，235（3）：133-136.
［30］　PALEJWALA NV，LAUER AK.Aflibercept：an update on recent milestones achieved［J］.Drugs Today（Barc），2014，50（12）：779-790.
［31］　HEIER JS，KOROBELNIK JF，BROWN DM，SCHMIDT-ERFURTH U，DO DV，MIDENA E，et al.Intravitreal Aflibercept for Diabetic Macular Edema：148-Week Results from the VISTA and VIVID Studies［J］.Ophthalmology，2016，123（11）：2376-2385.
［32］　WYKOFF CC，MARCUS DM，MIDENA E，KOROBELNIK JF，SAROJ N，GIBSON A，et al.Intravitreal aflibercept injection in eyes with substantial vision loss after laser photocoagulation for diabetic macular edema：subanalysis of the VISTA and VIVID randomized clinical trials［J］.JAMA Ophthalmol，2016，［Epub ahead of print］.
［33］　DU L，PENG H，WU Q，ZHU M，LUO D，KE X，et al.Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept［J］.Mol Vis，2015，21：185-193.
［34］　XU Y，RONG A，BI Y，XU W.Intravitreal conbercept injection with and without grid laser photocoagulation in the treatment of diffuse diabetic macular edema in real-life clinical practice［J］.J Ophthalmol，2016，2016：2143082.
［35］　QIAO G，DONG WJ，DAI Y，JIANG ZH，GUO HK.Diabetic macular edema in proliferative stage treated with anti-vascular endothelial growth factor agent and triamcinolone acetonide by laser-based strategies［J］.Int J Ophthalmol，2017，10（7）：1113-1119.
［36］　CAPITAO M，SOARES R.Angiogenesis and inflammation crosstalk in diabetic retinopathy［J］.J Cell Biochem，2016，117（11）：2443-2453.
［37］　TSILIMBARIS MK，PANAGIOTOGLOU TD，CHARISIS SK，ANASTASAKIS A，KRIKONIS TS，CHRISTODOULAKIS E.The use of intravitreal etanercept in diabetic macular oedema［J］.Semin Ophthalmol，2007，22（2）：75-79.
［38］　WU L，HERNANDEZ-BOGANTES E，ROCA JA，AREVALO JF，BARRAZA K，LASAVE AF.intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema：a pilot study from the Pan-American Collaborative Retina Study Group［J］.Retina，2011，31（2）：298-303.
［39］　AREVALO JF，SERRANO MA，WU L.Combined inhibition of tumor necrosis factor（TNF） and vascular endothelial growth factor（VEGF） for the treatment of macular edema of various etiologies：a short-term pilot study［J］.Eye（Lond），2013，27（4）：569-571.
［40］　SFIKAKIS PP，GRIGOROPOULOS V，EMFIETZOGLOU I，THEODOSSIADIS G，TENTOLOURIS N，DELICHA E，et al.Infliximab for diabetic macular edema refractory to laser photocoagulation：a randomized，double-blind，placebo-controlled，crossover，32-week study［J］.Diabetes Care，2010，33（7）：1523-1528.

相似文献/References:

[1]麻南 李丹 高付林 胡莲娜.玻璃体内注射贝伐单抗和贝伐单抗/曲安奈德联合用药治疗糖尿病性黄斑水肿疗效及安全性差异的荟萃分析[J].眼科新进展,2012,32(6):000.
[2]王玲,生侠,吴清静,等.红外线及自发荧光影像在糖尿病性黄斑水肿诊断中的价值[J].眼科新进展,2014,34(8):754.[doi:10.13389/j.cnki.rao.2014.0207]
　WANG Ling,SHENG Xia,WU Qing-Jing,et al.Value of infrared ray and auto fluorescence in diagnosis of diabetic macular edema[J].Recent Advances in Ophthalmology,2014,34(3):754.[doi:10.13389/j.cnki.rao.2014.0207]
[3]杨宇,田敏,吕红彬. 糖尿病视网膜病变的治疗进展[J].眼科新进展,2015,35(5):497.[doi:10.13389/j.cnki.rao.2015.0136]
　YANG Yu,TIAN Min,LV Hong-Bin. Recent advances in treatment of diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(3):497.[doi:10.13389/j.cnki.rao.2015.0136]
[4]李素华,高永峰. 比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2015,35(6):566.[doi:10.13389/j.cnki.rao.2015.0153]
　LI Su-Hua,GAO Yong-Feng. Efficacy of macular focal / grid photocoagulation combined with ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(3):566.[doi:10.13389/j.cnki.rao.2015.0153]
[5]夏风杰,闫峰,陆燕,等.糖尿病性黄斑水肿临床治疗进展[J].眼科新进展,2015,35(10):985.[doi:10.13389/j.cnki.rao.2015.0270]
　XIA Feng-Jie,YAN Feng,LU Yan,et al.Clinical treatment advances in diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(3):985.[doi:10.13389/j.cnki.rao.2015.0270]
[6]李秀云,朱艳,邓爱军.Ranibizumab治疗糖尿病性黄斑水肿短期疗效观察[J].眼科新进展,2016,36(1):067.[doi:10.13389/j.cnki.rao.2016.0019]
　LI Xiu-Yun,ZHU Yan,DENG Ai-Jun.Short-term efficacy of Ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2016,36(3):067.[doi:10.13389/j.cnki.rao.2016.0019]
[7]陈素芳,李亨辉,邵毅,等.非诺贝特在糖尿病性黄斑水肿中的临床研究[J].眼科新进展,2016,36(2):136.[doi:10.13389/j.cnki.rao.2016.0037]
　CHEN Su-Fang,LI Heng-Hui,SHAO Yi,et al.Clinical study of fenofibrate in diabetic macular edema[J].Recent Advances in Ophthalmology,2016,36(3):136.[doi:10.13389/j.cnki.rao.2016.0037]
[8]孙光丽,姜静,王成虎,等.高密度微脉冲激光联合玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿[J].眼科新进展,2017,37(3):279.[doi:10.13389/j.cnki.rao.2017.0070]
　SUN Guang-Li,JIANG Jing,WANG Cheng-Hu,et al.High-density micropulse photocoagulation combined with intravitreal injection of ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2017,37(3):279.[doi:10.13389/j.cnki.rao.2017.0070]
[9]宋志刚,魏少华.577 nm激光光凝联合玻璃体内注射康柏西普治疗糖尿病性黄斑水肿的效果观察[J].眼科新进展,2019,39(4):373.[doi:10.13389/j.cnki.rao.2019.0085]
　SONG Zhi-Gang,WEI Shao-Hua.Effect of 577 nm laser photocoagulation combined with intravitreal injection of conbercept on diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(3):373.[doi:10.13389/j.cnki.rao.2019.0085]
[10]赵子君,柯晓云.糖尿病性黄斑水肿治疗方式的研究进展[J].眼科新进展,2019,39(6):596.[doi:10.13389/j.cnki.rao.2019.0138]
　ZHAO Zi-Jun,KE Xiao-Yun.Recent advances in new emerging therapies of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(3):596.[doi:10.13389/j.cnki.rao.2019.0138]

更新日期/Last Update: 2018-03-05